|1.||Jones, Michael R: 19 articles (06/2014 - 02/2006)|
|2.||Misir, Soamnauth: 11 articles (05/2013 - 06/2009)|
|3.||Handelsman, Yehuda: 9 articles (07/2012 - 05/2009)|
|4.||Goldberg, Ronald B: 8 articles (05/2013 - 11/2007)|
|5.||Abby, Stacey L: 8 articles (07/2010 - 04/2006)|
|6.||Nagendran, Sukumar: 6 articles (07/2012 - 06/2009)|
|7.||Bays, Harold E: 6 articles (01/2012 - 04/2006)|
|8.||Lai, Yu-Ling: 6 articles (07/2010 - 11/2006)|
|9.||Hernandez-Triana, Eric: 5 articles (05/2013 - 09/2009)|
|10.||Rosenstock, Julio: 5 articles (07/2012 - 07/2010)|
|1.||Type 2 Diabetes Mellitus (MODY)
11/01/2007 - "Improved tolerability of newer BAS (eg, colesevelam hydrochloride) and a "new" appreciation of the historic benefits of these "old" therapeutic agents may lead to an increased treatment role for these drugs, particularly in hypercholesterolemic patients with type 2 diabetes mellitus."
07/01/2010 - "The safety and tolerability of colesevelam appear to be improved from that of older-generation bile acid sequestrants, with adverse effects similar to those with placebo in monotherapy and type 2 diabetes mellitus trials. "
08/01/2011 - "Clinical efficacy of colesevelam in type 2 diabetes mellitus."
02/01/2009 - "Literature search of colesevelam studies and abstracts assessing the benefits in managing type 2 diabetes mellitus. "
07/01/2014 - "Colesevelam for Type 2 diabetes mellitus: an abridged Cochrane review."
01/01/2010 - "In this study, colesevelam was found to be safe and effective for the management of LDL-C levels in adults with primary hypercholesterolemia."
01/01/2010 - "A 50-week extension study on the safety and efficacy of colesevelam in adults with primary hypercholesterolemia."
01/01/2010 - "To investigate the safety and efficacy of colesevelam in adults with primary hypercholesterolemia. "
09/01/2006 - "The aim of this study was to examine the effect of colesevelam HCl therapy (3.75 g/day for 6 weeks) on hs-CRP in patients with mild hypercholesterolemia in a randomized, double-blind, placebo-controlled study. "
07/01/2005 - "This study's aim was to determine effects of colesevelam HCl on sterol and bile acid excretion in patients with type IIa hypercholesterolemia. "
06/01/2014 - "In the hyperlipidemia studies, patients received colesevelam 1.5-4.5 g/day or placebo, alone or with a statin, for 4 weeks to 6 months. "
06/01/2014 - "In primary hyperlipidemia and in T2DM, colesevelam appeared to be generally as safe, well tolerated, and efficacious in patients aged ≥65 years as in those aged <65 years."
06/01/2014 - "In the hyperlipidemia analysis, colesevelam versus placebo produced similar mean reductions from baseline in LDL-C in older (-16.6 vs. +0.5 %) and younger (-13.7 vs. +0.4 %) patients. "
08/01/2013 - "The bile acid sequestrant colesevelam is indicated to reduce elevated LDL-C levels in adults with primary hyperlipidemia and in boys and postmenarchal girls (aged 10-17 years) with heterozygous FH. "
01/01/2005 - "Despite this, the role of colesevelam in the treatment of hyperlipidemia remains limited, particularly in the face of new lipid lowering agents. "
|4.||Prediabetic State (Prediabetes)
07/01/2010 - "Further study is warranted to determine whether colesevelam slows or prevents progression of prediabetes to type 2 diabetes."
11/01/2009 - "To evaluate the effects of colesevelam HCl in patients with prediabetes, a post-hoc analysis was conducted on data from a 24-week lipid-lowering study. "
09/01/2009 - "However, results of this trial will help to define the extent to which colesevelam HCl can help improve cardiometabolic risk factors for complications of type 2 DM in the first-line environment, and will also indicate the extent to which early intervention with colesevelam HCl can help to correct metabolic abnormalities associated with prediabetes."
05/01/2010 - "This article briefly reviews current treatment guidelines for patients with prediabetes and T2DM and the potential role of colesevelam in the management of prediabetes and T2DM with oral antidiabetes agents."
05/01/2009 - "This article reviews the place of colesevelam HCl in therapy (both for T2DM and prediabetes), the benefits of early, intensive treatment of T2DM, and the importance of safe glycemic control later in the disease process."
06/01/2013 - "The combination of colesevelam with rosuvastatin 5 mg/day may be associated with favorable effects on markers of insulin resistance compared with rosuvastatin 10 mg/day in patients with hypercholesterolemia and IFG. "
06/01/2013 - "It is not known whether the combination of colesevelam plus low-dose statin has different effects on insulin resistance versus higher-dose statin in patients with impaired fasting glucose (IFG) and hypercholesterolemia. "
03/01/2010 - "Colesevelam improves insulin resistance in a diet-induced obesity (F-DIO) rat model by increasing the release of GLP-1."
10/01/2013 - "Colesevelam offset the negative glycemic effects of statins and niacin in subjects with insulin resistance or impaired glucose tolerance. "
03/01/2010 - "To investigate how colesevelam (CL) HCl improves hyperglycemia, studies were conducted in diet-induced obesity (F-DIO) rats, which develop insulin resistance when fed a high-energy (high fat/high sucrose) diet (HE). "
|6.||Glucagon-Like Peptide 1 (GLP 1)
|7.||Cholestyramine Resin (Questran)
|2.||Ambulatory Care (Outpatient Care)